The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger

A new proof of concept has big financial implications However, that doesn't stop NTLA-2001 from making a massive and likely permanent improvement to a patient's health. If the candidate is eventually approved for sale, it will likely be branded as a functional cure for the condition. That brings us to the new development that's bullish for Intellia. So far, none of Intellia's competitors have been able to produce the same evidence. Intellia Therapeutics (NTLA 0.79%) just published some new data that suggest ...